Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

TRK Inhibitor Active in Treatment-Refractory Glioblastoma

2.

CAR T-Cell Therapy in Functional High-Risk Multiple Myeloma

3.

Squeezing through tiny blood vessels may trigger melanoma cells to spread

4.

mRNA-based COVID vaccines generate improved responses to immunotherapy

5.

Men With Prostate Cancer Experience Less Hot Flashes When Using an Affordable Drug.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot